Analysis of the factors influencing the survival time of patients with sarcomatoid renal cell carcinoma

被引:3
作者
Wang, Yu-Sheng [1 ]
Shuang, Wei-Bing [1 ]
Yin, Ke-Qiang [1 ]
Tong, Xu-Nan [1 ]
Xia, Man-Cheng [1 ]
Yang, Hao-Sen [1 ]
机构
[1] Shanxi Med Univ, Hosp 1, Dept Urol, 85 Jiefang Rd, Yingze 030001, Shanxi, Peoples R China
关键词
sarcomatoid renal cell carcinoma; survival time; survival analysis; Cox proportional hazards model; Kaplan-Meier estimate; log-rank test; PROGNOSTIC-FACTOR; SYSTEMIC THERAPY; DIFFERENTIATION; IMMUNOTHERAPY; NEPHRECTOMY; GEMCITABINE;
D O I
10.3892/mco.2019.1900
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of the present study was to identify the factors influencing the survival time of patients with sarcomatoid renal cell carcinoma (SRCC). Between January 2000 and September 2017, a total of 21 patients were enrolled, all of whom were diagnosed with SRCC. In total, eight prognostic factors were analyzed using the Kaplan-Meier estimator, a log-rank test and Cox's proportional hazards model. The log-rank test results revealed that there was a significant association between the proportion of sarcoma elements and survival time of patients with SRCC (P<0.05). In addition, there was a significant association between post-operative drug treatment and SRCC survival time (P<0.05). The results of the Kaplan-Meier estimate demonstrated that the survival curve of post-operative drug treatment was significantly greater compared with the survival curve of patients who did not undergo drug treatment (P<0.05). The survival curve of patients with a proportion of sarcoma elements <50% was significantly greater compared with the survival curve of patients with a proportion of sarcoma elements >= 50% (P<0.05). Furthermore, the Cox's proportional hazards model revealed that the mortality risk in post-operative patients without drug treatment was 5.822 times greater compared with that of patients with drug treatment (P<0.05). Mortality risk in patients with a proportion of sarcoma elements >= 50% was 4.682 times higher compared with that of patients with sarcoma elements <50% (P<0.05). Finally, post-operative drug therapy was revealed to be a protective factor which significantly affected the survival time of patients with SRCC [risk ratio (RR)=0.172], in addition to the proportion of sarcoma elements >= 50% (RR=4.682). In conclusion, drug therapy should be promoted upon patient diagnosis with SRCC and attention should be given to the proportion of sarcomatoid components.
引用
收藏
页码:405 / 410
页数:6
相关论文
共 38 条
  • [1] Systemic therapy following metastasectomy for renal cell carcinoma: Using insights from other clinical settings to address unanswered questions
    Appleman, Leonard J.
    Maranchie, Jodi K.
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (01) : 17 - 22
  • [2] Bono AV, 1997, EUR UROL, V31, P47
  • [3] Sarcomatoid renal cell carcinoma: Biologic behavior, prognosis, and response to combined surgical resection and immunotherapy
    Cangiano, T
    Liao, J
    Naitoh, J
    Dorey, F
    Figlin, R
    Belldegrun, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) : 523 - 528
  • [4] CHEN JH, 2007, J KUN MING MED U, V29, P483
  • [5] TREATMENT OF SARCOMATOID RENAL-CELL CARCINOMA - IS THERE A ROLE FOR CHEMOTHERAPY
    CULINE, S
    BEKRADDA, M
    TERRIERLACOMBE, MJ
    DROZ, JP
    [J]. EUROPEAN UROLOGY, 1995, 27 (02) : 138 - 141
  • [6] DINGWEI YE, 2014, CHINE J UROL, V35, P401
  • [7] Phase I evaluation of sequential doxorubicin plus gemcitabine then ifosfamide plus paclitaxel plus cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract
    Dodd, PM
    McCaffrey, JA
    Hilton, S
    Mazumdar, M
    Herr, H
    Kelly, WK
    Icasiano, E
    Boyle, MG
    Bajorin, DF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) : 840 - 846
  • [8] ESCUDIER B, 2005, J CLIN ONCOL, V23, P4510
  • [9] GAO Y, 2017, TRANSL SURG, V2, P74
  • [10] Survival in patients with rare subtypes of renal cell carcinoma
    Grabowski, M
    Huzarski, T
    Lubinski, J
    Sikorski, A
    [J]. BJU INTERNATIONAL, 2002, 89 (06) : 599 - 600